SCHEMBL3574804

SCHEMBL3574804

CCOC(=O)Cc1c(C)c(Sc2ccc(Cl)cc2Cl)n2cc(F)ccc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 2/20 0.52
TDP1 Q9NUW8 1/20 0.38
PTGS2 P35354 2/20 0.37
MAPT P10636 2/20 0.36
TSHR P16473 2/20 0.36
HSD17B10 Q99714 2/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
ALOX15 P16050 1/20 0.36
CYP2C19 P33261 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.35
KDM4E B2RXH2 2/20 0.35
ATM Q13315 1/20 0.35
POLB P06746 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2769710 0.88 PTGDR2 (0.66) PTGDR2PTGS2ALDH1A1MEN1KMT2A
SCHEMBL3569319 0.88 PTGDR2 (0.65) PTGDR2PTGS2MAPTTSHRCYP1A2
SCHEMBL3572270 0.80 PTGDR2 (0.80) PTGDR2PTGS2ALDH1A1MEN1KMT2A
SCHEMBL2771396 0.79 PTGDR2 (0.50) PTGDR2PTGS2MAPTTSHRHSD17B10
SCHEMBL3304453 0.78 PTGDR2 (0.46) PTGDR2MAPTALDH1A1CYP1A2CYP3A4
SCHEMBL3568365 0.78 PTGDR2 (0.64) PTGDR2PTGS2ALDH1A1POLBMEN1
SCHEMBL3569716 0.77 PTGDR2 (0.45) PTGDR2PTGS2MAPTTSHRALDH1A1
SCHEMBL2770310 0.77 PTGDR2 (0.54) PTGDR2PTGS2KMT2A
SCHEMBL3300027 0.77 PTGDR2 (0.61) PTGDR2TDP1TSHRHSD17B10ALDH1A1
SCHEMBL2769552 0.76 PTGDR2 (0.82) PTGDR2PTGDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100010034-A1 CRTH2 ANTAGONISTS ARGENTA DISCOVERY LIMITED (GB) 2010-01-14 US disclosed
EP-2094266-A1 CRTH2 ANTAGONISTS Argenta Discovery Limited (GB) 2009-09-02 EP disclosed
WO-2008074966-A1 CRTH2 ANTAGONISTS ARGENTA DISCOVERY LIMITED (GB) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100010034-A1 CRTH2 ANTAGONISTS HRH2, MDH2, HRH1 PTGDR2 167/4885TDP1 4769/4885PTGS2 426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.